CASI Pharmaceuticals Inc
CASI
Market Cap$29.21M
Close$
$3.55
88.3% upside
Current Fair Value
88.3% upsideUndervalued by 88.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $29.21 Million |
|---|---|
| Enterprise Value | $40.36 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.56 |
| Beta | 0.76 |
| Outstanding Shares | 15,492,581 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.74 |
|---|---|
| PEG | -0.92 |
| Price to Sales | 1.89 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.9 |
| Enterprise Value to EBIT | -1.39 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.61 |
| Debt to Equity | 13.3 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CASI Pharmaceuticals Inc
CEO: Wei-Wu He CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on...